Nanomedicine / nanotechnology

Megan Thomas talks to Molly Stevens, John Black Professor at Oxford University and Research Director for Biomedical Materials at Imperial College London. MT: Where do you work, and can you tell us what you’re working on at the moment? MS: I am going through an exciting transition period. After a terrific and highly productive era […]

Aviceda Therapeutics has dosed the first patient in its Phase II SIGLEC trial investigating AVD-104 as a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). AVD-104 is a novel glycan-coated nanoparticle, supported by a strong pre-clinical in vivo efficacy and safety profile. “I am honoured to be the first to dose a […]

SiSaf is to collaborate with the University of Leipzig, Germany, to develop targeted micro interfering RNAs (miRNA) for the treatment of cancer, with an initial focus on pancreatic cancer.   The collaboration will combine SiSaf’s expertise in RNA delivery using its Bio-Courier silicon-stabilised hybrid lipid nanoparticles (sshLNPs) and the University of Leipzig’s expertise in miRNA targeting […]

Researchers have made it possible to see at the nano level where a medicinal drug ends up in the cells and how much of it is needed for optimum treatment.  The technique enables the development of new pharmaceuticals and tailored treatments for diseases that have not previously been treatable. The advance also makes it necessary […]

Oregon State University College of Pharmacy scientists have shown that lipid nanoparticles and messenger RNA could treat blindness associated with a rare genetic condition.  Researchers developed nanoparticles able to penetrate the neural retina and deliver mRNA to the photoreceptor cells whose proper function makes vision possible.  The study, led by OSU Associate Professor of Pharmaceutical […]

Here, we speak with two of the keynote speakers at this year’s Drug Discovery 2022, Molly Stevens, Professor of Biomedical Materials and Regenerative Medicine at Imperial College London, and Rab Prinjha, VP Head of Immunology Research Unit at GlaxoSmithKline, about the insights they will be sharing and what they see as the drivers of the drug discovery […]

University of Queensland researchers have pioneered a new chemical process to manufacture molecules that are the building blocks for lifesaving medicines, vaccines and energy storage materials. Professor Matt Trau from UQ’s Australian Institute for Bioengineering and Nanotechnology (AIBN) has been awarded an ARC Laureate Fellowship worth $2.9 million to further understand and develop the process. […]

A potential improved treatment for two of the leading causes of blindness – age and diabetes-related eye problems – has been demonstrated in research involving University of Queensland expert Professor Di Yu of the UQ Diamantina Institute, who collaborated with scientists from the Chinese Academy of Sciences and Beijing Chaoyang Hospital to address an issue […]

The Infection Innovation Consortium (iiCON) has launched The Nanotherapeutics Hub, based at the University of Liverpool in the UK, part of Liverpool’s Centre of Excellence for Long-acting Therapeutics (CELT). The agreement will see The Nanotherapeutics Hub work with iiCON to support companies looking to develop nanotherapeutics to combat infectious diseases and access the nanomedicine market, […]

Treatment for fungal lung infections could be more efficient when medication is inhaled using nanoparticle technology, according to research from the University of Central Lancashire (UCLan). The early findings of the study published in Springer Nature: Journal of Nanobiotechnology are of particular significance as many people with lung diseases that cause immune dysregulation, such as […]

Evonetix collaborates with imec to scale-up chip-based technology production for third generation DNA synthesis platform. EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced it has partnered with imec, a world-leading research and innovation hub active in the fields of nanoelectronics and digital technologies, […]

30 June 2020 Image: Glen Carrie In lab tests, virus-like DNA structures coated with viral proteins provoke a strong immune response in human B cells, by Ann Trafton, MIT News Office By folding DNA into a virus-like structure, MIT researchers have designed HIV-like particles that provoke a strong immune response from human immune cells grown in a […]

Unlocking the potential of Extracellular Vesicles: from single molecules to novel therapeutics By Dr Anna Caballe and Dr Katarzyna Ginda-Makela As part of normal homeostasis, cells release different types of small-sized membrane vesicles to traffic analytes across membranes, communicate with other cells and remove unwanted cell content. These vesicles can range in size from 30nm […]

By Dr Steve Arlington and John Wise As part of its mission to help members anticipate and prepare for changes in the pharmaceutical industry, The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might look like in 2030, in particular how the […]

2030 Life Sciences and Health in the Digital Age (Part 1) By Dr Steve Arlington and John Wise One of the key ways in which The Pistoia Alliance works with its members is to help them not just deal with the problems of today, but also to look ahead, to anticipate how the industry is […]

Systems Pharmacology: When multi-targeting is advantageous By Dr Kirkwood A. Pritchard Jr, Dr Dustin P. Martin and Dr Stephen Naylor The safety and efficacy of therapeutic drugs still requires improvement. In part this is due to the promiscuity of individual drugs, which on average can interact with an estimated 6-28 other off-target moieties. However, the […]